157 related articles for article (PubMed ID: 12915681)
21. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system.
Hirono Y; Yoshimoto T; Suzuki N; Sugiyama T; Sakurada M; Takai S; Kobayashi N; Shichiri M; Hirata Y
Endocrinology; 2007 Apr; 148(4):1688-96. PubMed ID: 17218415
[TBL] [Abstract][Full Text] [Related]
22. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
Brown NJ; Kumar S; Painter CA; Vaughan DE
Hypertension; 2002 Dec; 40(6):859-65. PubMed ID: 12468570
[TBL] [Abstract][Full Text] [Related]
23. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.
Kasama S; Toyama T; Sumino H; Matsumoto N; Sato Y; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2007 Dec; 48(12):1993-2000. PubMed ID: 18006623
[TBL] [Abstract][Full Text] [Related]
24. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
Neves MF; Amiri F; Virdis A; Diep QN; Schiffrin EL;
Can J Physiol Pharmacol; 2005 Nov; 83(11):999-1006. PubMed ID: 16391708
[TBL] [Abstract][Full Text] [Related]
25. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H
Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
[TBL] [Abstract][Full Text] [Related]
26. Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions.
Otani H; Otsuka F; Inagaki K; Suzuki J; Miyoshi T; Kano Y; Goto J; Ogura T; Makino H
Endocrinology; 2008 Jun; 149(6):2816-25. PubMed ID: 18308844
[TBL] [Abstract][Full Text] [Related]
27. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture.
Skurk T; Lee YM; Hauner H
Hypertension; 2001 May; 37(5):1336-40. PubMed ID: 11358950
[TBL] [Abstract][Full Text] [Related]
29. Endogenous NO regulates plasminogen activator inhibitor-1 during angiotensin-converting enzyme inhibition.
Brown NJ; Muldowney JA; Vaughan DE
Hypertension; 2006 Mar; 47(3):441-8. PubMed ID: 16432054
[TBL] [Abstract][Full Text] [Related]
30. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function.
Ridker PM; Gaboury CL; Conlin PR; Seely EW; Williams GH; Vaughan DE
Circulation; 1993 Jun; 87(6):1969-73. PubMed ID: 8504511
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study.
Koh KK; Chung WJ; Ahn JY; Han SH; Kang WC; Seo YH; Ahn TH; Choi IS; Shin EK
Atherosclerosis; 2004 Nov; 177(1):155-60. PubMed ID: 15488878
[TBL] [Abstract][Full Text] [Related]
32. Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
Tanabe A; Naruse M; Hara Y; Sato A; Tsuchiya K; Nishikawa T; Imaki T; Takano K
J Hypertens; 2004 May; 22(5):1017-23. PubMed ID: 15097243
[TBL] [Abstract][Full Text] [Related]
33. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
Brown L; Duce B; Miric G; Sernia C
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S143-8. PubMed ID: 9892155
[TBL] [Abstract][Full Text] [Related]
34. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
Koh KK; Ahn JY; Han SH; Kim DS; Jin DK; Kim HS; Shin MS; Ahn TH; Choi IS; Shin EK
J Am Coll Cardiol; 2003 Sep; 42(5):905-10. PubMed ID: 12957441
[TBL] [Abstract][Full Text] [Related]
35. Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats.
Kobayashi N; Nakano S; Mita S; Kobayashi T; Honda T; Tsubokou Y; Matsuoka H
J Pharmacol Exp Ther; 2002 May; 301(2):459-66. PubMed ID: 11961044
[TBL] [Abstract][Full Text] [Related]
36. Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism.
Neves MF; Virdis A; Schiffrin EL
J Hypertens; 2003 Jan; 21(1):189-98. PubMed ID: 12544451
[TBL] [Abstract][Full Text] [Related]
37. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
38. Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke.
Saad MA; Abbas AM; Boshra V; Elkhateeb M; El Aal IA
Acta Physiol Hung; 2010 Jun; 97(2):159-71. PubMed ID: 20511125
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
Chen HH; Redfield MM; Nordstrom LJ; Cataliotti A; Burnett JC
Am J Physiol Renal Physiol; 2003 May; 284(5):F1115-9. PubMed ID: 12676739
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
Tsutamoto T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
Hypertens Res; 2010 Feb; 33(2):118-22. PubMed ID: 19927151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
